Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.
Popular Weight Loss Drugs Ozempic, Wegovy May Lower Alzheimer's Disease Risk
Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of developing the disease, the study found
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study
The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer's disease, a new study published Thursday finds.
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.
Novo’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.
Ozempic linked to lower Alzheimer’s risk in people with Type 2 diabetes
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study
In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.
News Medical
19m
Brain aging may hold the key to predicting Alzheimer’s risk
Research reveals advanced brain aging in older adults correlates with cognitive decline and Alzheimer's risk, highlighting ...
2h
Breakthrough Discovery: Freezing Alzheimer’s Progress by Pausing Amyloid Fibrils
Researchers have identified a key mechanism in the development of Alzheimer's disease involving the growth and pause of ...
STAT
14h
Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more
By 2021, nearly 2,000 volunteers had answered the call to test an experimental
Alzheimer’s
drug known as BAN2401. For Eisai ...
health enews
18h
Do’s and don’ts: Caring for a loved one with Alzheimer’s disease
When caring for a loved one with Alzheimer’s disease, be patient and repeat when necessary, plan ahead and use memory cues.
6d
on MSN
Alzheimer's disease might damage brain in two phases
Alzheimer's disease might damage the brain in two distinct phases, a new study suggests. An early phase that occurs slowly ...
News Medical on MSN
2h
Semaglutide may lower Alzheimer's risk in type 2 diabetes patients
Researchers at the Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk ...
3d
on MSN
Alzheimer's disease may damage the brain in two phases
Alzheimer's disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping ...
WKBW
10h
Researchers at UB working to create vaccine to treat Alzheimer's disease
There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
United Kingdom
drugs
Donanemab
Massachusetts
Feedback